News
JAZZ
158.58
+1.65%
2.57
What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder
Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea (OSA).  SVB Leerink says its view on Sunosi has not chang...
Benzinga · 2d ago
IBD 50 Stocks To Watch: This Pharma Stock Rides Health Care Wave
Jazz Pharmaceuticals stands out in the IBD 50 as it rides the wave of the health care sector on concerns of a looming recession.
Investor's Business Daily · 2d ago
JAZZ's Late-Stage Multiple Sclerosis Study on Nabiximols Fails
JAZZ's phase III study evaluating nabiximols oromucosal spray for clinical measures of spasticity in multiple sclerosis patients fails to meet the primary endpoint.
Zacks · 2d ago
Axsome draws 36% hike for price target at Cantor on prospects for Sunosi
Cantor Fitgerald raised its price target on commercial-stage biopharma Axsome Therapeutics (NASDAQ:<a href="https://seekingalpha.com/symbol/AXSM?utm_medium=referral&utm_source=webull.com" title="Axsome Therapeut...
Seekingalpha · 2d ago
Jazz Pharma's Cannabidiol Mixture Spray Misses Primary Goal In Multiple Sclerosis Spasticity
Benzinga · 3d ago
Jazz cannabis spray for multiple sclerosis fails phase 3 trial
Jazz Pharmaceuticals (NASDAQ:JAZZ) said its cannabis-based nabiximols oromucosal spray (JZP378) failed to meet the main goal of a late-stage study in patients with multiple sclerosis (MS) spasticity. MS is a potentially disabling disease affecting
Seekingalpha · 3d ago
Jazz Pharmaceuticals Announces Top-line Results From Phase 3 Trial Evaluating Nabiximols Oromucosal Spray In Adult Participants With Multiple Sclerosis Spasticity; Trial Did Not Meet Primary Endpoint
Nabiximols oromucosal spray continues to be evaluated in ongoing clinical trials in multiple sclerosis spasticity DUBLIN, June 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced
Benzinga · 3d ago
Jazz Pharmaceuticals Says First of Phase 3 Trials of Cannabis-Based Multiple Sclerosis Drug Didn't Meet Primary Endpoint
MT Newswires · 3d ago
Switzerland Removes Medical Marijuana Access Limitations As Demand Rises
The Swiss government confirmed that it will remove limitations on medical marijuana use, starting August 1st, 2022. 
Benzinga · 06/23 14:59
Leisuretown: Diplo And Rob Dyrdek's New Cannabis Seltzers Launch In California Via Agreement With HERBL
Thomas Wesley Pentz, better known for his artistic name, Diplo, partnered with California cannabis beverage company Leisuretown, professional skateboarder Rob Dyrdek and cannabis supply chain company HERBL, to launch a new line of cannabis drinks under the...
Benzinga · 06/23 11:56
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks · 06/22 13:40
FDA stalled on CBD for now: Analyst
FDA expresses interest in more studies of CBD but no real action is expected without a push from Congress, according to Cowen analyst.
marketwatch.com · 06/15 14:33
Jazz to start clinical trial for tumor candidate after FDA nod
Jazz Pharmaceuticals (NASDAQ:JAZZ) is set to initiate a clinical trial for pan-RAF inhibitor JZP815 developed by its partner Redx after the U.S. Food and Drug Administration (FDA) cleared its Investigational
Seekingalpha · 06/15 12:13
Jazz initiated Buy at UBS on underappreciated potential of cannabidiol drug
UBS has launched its coverage on Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy rating and a $194 per share target, arguing that investors have underestimated the growth prospects of Ireland-based pharma’s
Seekingalpha · 06/14 17:03
4 Analysts Have This to Say About Jazz Pharmaceuticals
Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter:
Benzinga · 06/14 15:07
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
Upgrades
Benzinga · 06/14 14:03
UBS Initiates Coverage on Jazz Pharmaceuticals With Buy Rating, $194 Price Target
MT Newswires · 06/14 11:54
Insider Sell: Jazz Pharmaceuticals
MT Newswires · 06/13 07:11
Euro Food Agency Concerned About Health Effects Of CBD, Asks For More Research
The European Food Safety Authority (EFSA) is asking for more research on the effects of CBD on humans.
Benzinga · 06/10 15:55
North Carolina House Says Yes To Bill Allowing FDA-Approved THC Drugs, Will This Kill Full Medical Marijuana Legalization?
The North Carolina House passed Senate Bill 448, legalizing FDA-approved THC medications in a 92-9 vote, reported The Carolina Journal.
Benzinga · 06/09 14:47
More
Webull provides a variety of real-time JAZZ stock news. You can receive the latest news about Jazz Pharmaceuticals Plc through multiple platforms. This information may help you make smarter investment decisions.
About JAZZ
Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.